FDA Approves Cefepime/Zidebactam Injection, Raising Sterile Manufacturing and QA Readiness Questions

Sterile manufacturing facilities and QA teams now have a new combination injectable antibiotic to account for in their production pipelines: the FDA has approved Cefepime and Zidebactam Injection, a beta-lactam/beta-lactamase inhibitor combination indicated against gram-negative pathogens including Enterobacterales and Pseudomonas aeruginosa.

The approved dosing regimen, 2 g cefepime and 1 g zidebactam administered by intravenous infusion over one hour every eight hours, establishes the pharmacokinetic parameters that will anchor process validation and formulation development work. Susceptibility breakpoints have been set at MIC ≤ 8 mcg/mL for both Enterobacterales and Pseudomonas aeruginosa, with disk diffusion criteria using 30/30 mcg cefepime/zidebactam impregnated paper disks. These interpretive criteria apply specifically to patients with an estimated glomerular filtration rate of 60 mL/min or greater, a clinical constraint that informs labeling and, downstream, any post-approval change management under 21 CFR Part 211.

For QA directors and regulatory affairs leads, the fixed-ratio combination format introduces compounding sterility assurance considerations. Cefepime is an established cephalosporin with known stability profiles; zidebactam is a novel bicyclic boronate beta-lactamase inhibitor. Compatibility and degradation behavior of the combined formulation under terminal sterilization or aseptic fill-finish conditions will require validation data that does not yet have a broad industry reference base. Facilities preparing to license or contract-manufacture this product should expect early engagement with ICH Q10 pharmaceutical quality system requirements, particularly around knowledge management for a novel active moiety.

The combination's activity against carbapenem-resistant organisms positions it within a therapeutic class under sustained regulatory scrutiny. Facilities entering this space should anticipate that inspection readiness, CAPA documentation, and sterility assurance level justifications will be reviewed with the same rigor applied to other critical-care injectables.

The next measurable checkpoint for manufacturing stakeholders will be the publication of full prescribing information and any associated FDA guidance on susceptibility testing standardization, both of which will define the analytical method validation requirements facilities must satisfy before commercial release.

Source: U.S. Food and Drug Administration, What's New: Drugs RSS Feed, via FDA.gov, May 29, 2026.